The Pulmonary Fibrosis Foundation added two experienced ILD specialists to its board as it advances a five-year strategic ...

Celea Therapeutics’ $180M financing will support a Phase 3 IPF drug trial comparing deupirfenidone with Esbriet.

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs, leading to breathing difficulties, dry cough, muscle aches, and unintended weight loss. Because these symptoms also are ...

Ofev (nintedanib) is an anti-fibrotic medicine marketed by Boehringer Ingelheim that was approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the U.S. in 2014 and in Europe in 2015.

Fatigue, sometimes described as overwhelming tiredness or physical malaise, is a common symptom of pulmonary fibrosis (PF) patients. Generally, fatigue is characterized by a lack of energy that does ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

Pulmonary fibrosis (PF) is a respiratory disease characterized by fibrosis, or tissue scarring, in the lungs. To function normally, lungs need to be stretchy and elastic like a balloon in order to ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Esbriet (pirfenidone) is an oral treatment for idiopathic pulmonary fibrosis (IPF) that was originally developed by Intermune, which later merged with Roche. Esbriet was first approved in the European ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...